DurAVR™ THV EU-EFS
← catalyst calendarSponsored by Anteris Technologies Ltd. (industry) · AVR — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Device feasibility
Enrollment
40estimated
Sites
1
Country
Denmark
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-21 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Symptomatic Aortic Stenosis
- Severe Aortic Valve Stenosis
- Aortic Valve Calcification
- Aortic Valve Failure
- Aortic Valve Disease
Intervention
- Device: DurAVR™ THV System
Primary outcome
what the primary-completion date above is the date OFAll-cause mortality or disabling stroke
measured 30 Days
Permalink · AVR's whole pipeline · Catalyst calendar · Every registered study · What changed